Scholarlink

Background <p>Psoriasis is a chronic immune-mediated inflammatory skin disorder, with plaque psoriasis being the most common clinical subtype, especially in elderly patients. Conventional therapies often provide suboptimal outcomes, necessitating the exploration of novel treatment approaches. This study evaluates the clinical efficacy of combining Secukinumab with Calcipotriol Cream in elderly patients with moderate to severe psoriasis.</p> Methods <p>A total of 160 elderly patients (≥ 65 years) with plaque psoriasis were retrospectively analyzed between January 2020 and December 2024. All patients received baseline therapy with oral acitretin and topical clobetasol. The observation group (<i>n</i> = 80) additionally received secukinumab and calcipotriol cream. The control group (<i>n</i> = 80) received baseline therapy only. The primary endpoint was overall clinical efficacy based on Psoriasis Area and Severity Index (PASI) improvement. Secondary endpoints included changes in PASI scores, Dermatology Life Quality Index (DLQI), skin barrier parameters (stratum corneum hydration and sebum content), and incidence of adverse events over 12 weeks.</p> Results <p>The total efficacy rate was significantly higher in the observation group than in the control group (90.0% vs. 72.5%, χ² = 8.306, <i>P</i> = 0.040). PASI scores were significantly reduced in both groups, with a greater reduction observed in the observation group (16.12 ± 3.13 vs. 18.98 ± 3.92; <i>P</i> &lt; 0.001). Improvements in stratum corneum hydration (54.08 ± 6.05 vs. 50.20 ± 5.74; <i>P</i> &lt; 0.001) and sebum content (138.20 ± 12.39 vs. 129.72 ± 10.68; <i>P</i> &lt; 0.001) were also greater in the observation group. DLQI scores improved more significantly in the observation group (7.82 ± 1.05 vs. 9.52 ± 1.38; <i>P</i> &lt; 0.001). Adverse events were infrequent and comparable between groups (<i>P</i> = 0.168). Post hoc power analysis confirmed sufficient statistical power (&gt; 80%) across all primary endpoints.</p> Conclusions <p>This retrospective study suggests that secukinumab combined with calcipotriol cream improves clinical outcomes and quality of life with good tolerability in elderly patients with moderate to severe psoriasis, supporting its potential therapeutic utility.</p> Clinical trial <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical efficacy analysis of secukinumab combined with calcipotriol cream in the treatment of moderate to severe psoriasis in elderly patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月25日

查看全文
  • Ling Lin,
  • Wei Li,
  • Qian Li,
  • Xinjing Gao,
  • Jingxin Zeng,
  • Xin Zhou,
  • Weiyu Liu,
  • Xuelian Zhong,
  • Yunqing Yang,
  • Xibao Zhang,
  • Quan Luo

摘要

Background

Psoriasis is a chronic immune-mediated inflammatory skin disorder, with plaque psoriasis being the most common clinical subtype, especially in elderly patients. Conventional therapies often provide suboptimal outcomes, necessitating the exploration of novel treatment approaches. This study evaluates the clinical efficacy of combining Secukinumab with Calcipotriol Cream in elderly patients with moderate to severe psoriasis.

Methods

A total of 160 elderly patients (≥ 65 years) with plaque psoriasis were retrospectively analyzed between January 2020 and December 2024. All patients received baseline therapy with oral acitretin and topical clobetasol. The observation group (n = 80) additionally received secukinumab and calcipotriol cream. The control group (n = 80) received baseline therapy only. The primary endpoint was overall clinical efficacy based on Psoriasis Area and Severity Index (PASI) improvement. Secondary endpoints included changes in PASI scores, Dermatology Life Quality Index (DLQI), skin barrier parameters (stratum corneum hydration and sebum content), and incidence of adverse events over 12 weeks.

Results

The total efficacy rate was significantly higher in the observation group than in the control group (90.0% vs. 72.5%, χ² = 8.306, P = 0.040). PASI scores were significantly reduced in both groups, with a greater reduction observed in the observation group (16.12 ± 3.13 vs. 18.98 ± 3.92; P < 0.001). Improvements in stratum corneum hydration (54.08 ± 6.05 vs. 50.20 ± 5.74; P < 0.001) and sebum content (138.20 ± 12.39 vs. 129.72 ± 10.68; P < 0.001) were also greater in the observation group. DLQI scores improved more significantly in the observation group (7.82 ± 1.05 vs. 9.52 ± 1.38; P < 0.001). Adverse events were infrequent and comparable between groups (P = 0.168). Post hoc power analysis confirmed sufficient statistical power (> 80%) across all primary endpoints.

Conclusions

This retrospective study suggests that secukinumab combined with calcipotriol cream improves clinical outcomes and quality of life with good tolerability in elderly patients with moderate to severe psoriasis, supporting its potential therapeutic utility.

Clinical trial

Not applicable.